Neratinib in patients with HER2+ breast cancer: a multi-centric, multi-national, prospective, longitudinal, non-interventional study in Switzerland, Germany and Austria. rEal-LifE pAN-HER-blOckade with neRatinib: ELEANOR
Neratinib in patients with HER2+ breast cancer: a multi-centric, multi-national, prospective, longitudinal, non-interventional study in Switzerland, Germany and Austria. rEal-LifE pAN-HER-blOckade with neRatinib: ELEANOR
Neratinib in patients with HER2+ breast cancer: a multi-centric, multi-national, prospective, longitudinal, non-interventional study in Switzerland, Germany and Austria. rEal-LifE pAN-HER-blOckade with neRatinib: ELEANOR
Status
Status :
Completed
Type of study
RWE
Min. Age
18
Years old
Max. Age
-
Gender
Female
Therapeutic area :
Oncology
Disease :
Breast cancer HER2+
Study medication :
Neratinib (NERLYNX®)
Phase :
RWE
Start Date :
July 02, 2020
End date :
September 05, 2024
Study ID :
NIS07075
CT.gov Number :
NCT04388384
Sponsor(s) or Co-Sponsor(s) :
Pierre Fabre Pharma AG (Switzerland), Pierre Fabre Pharma GmbH (Germany), Pierre Fabre Pharma Austria
Send by email